To the Editor:We would like to share ideas on the publication “Thrombocytopenia in a teen with sickle cell disease following COVID‐19 vaccination.”
The adverse event of new COVID‐19 vaccine is an interesting issue. For a case with underlying disease, there might be a possible risk. Thrombocytopenia is a commonly reported adverse event after COVID‐19 vaccination and might be associated with automimmunity.
For a person with sickle cell disease, the problem of a thrombohemostatic disorder following vaccination is possible. Not only immunopathological process but also change of blood viscosity might be induced. In general, after COVID‐19 vaccination, there will be increased blood viscosity that can further result in a thrombohemostatic disorder.
In sickle cell anemia, there is background high blood viscosity
; hence, there might be an increasing chancefor a high blood viscosity problem inducing clot and relative thrombocytopenia.
CONFLICT OF INTEREST
The authors declare that there is no conflict of interest.